1. Pink Sheet
  2. >>Compliance

Who Will Reap The BIOSECURE Spoils? US Industry Boost Not Guaranteed

 
• By Sarah Karlin-Smith

With the BIOSECURE Act halfway to congressional approval, stakeholders are pushing for a financial boost to ensure the US gains the business Chinese companies will lose, but that may be a big lift.

man in suit walking up hill with big bag of money on his back
Half of the goal of BIOSECURE may require more legislation, which will be a big lift in the US. • Source: Shutterstock

National security and supply chain security have been the driving political arguments behind the push for the BIOSECURE Act, a bill that would force the separation of the US pharmaceutical industry from certain Chinese manufacturing and contract development companies.

Key Takeaways

  • To truly fulfill all the national security and supply chain rhetoric used to justify the BIOSECURE Act, US lawmakers likely need to provide a substantial chunk of federal funds to the biopharma industry.

  • The more likely scenario is other Chinese companies or other countries’ businesses reap much of the BIOSECURE benefits

But the legislation, which cleared the US House of Representatives 9 September on a 306-81 vote and is pending in the Senate, still has industry and lawmakers considering how

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Distribution/Supply Chain

More from Compliance